Ann: SPL7013 shows potent antiviral activity in RSV, page-15

I have been saying for a while that this could be very significant. They have not yet specified the Rhinovirus but I suspect they are testing that too. And if it works for H1N1 influenza it quite possibly (even probably) works more broadly.

What we have here is a preventative and early post infection treatment for a huge number of respiratory viruses. It is the equivalent of penicillin for bacterial disease. And so far it doesn't look like it is going to need a prescription.

There will be one in our medicine chest as soon as it become available:

For when the grandchildren arrive with colds,
For when exposed to anyone who has a cold or flu,

COVID-19 has a way to go and the vaccines are not 100% and immunity is quite possibly short term (as most flu shots are).

This my fellow shareholders has HUGE potential! but just potential!

My only misgiving has been the ability of the company to negotiate and execute effective marketing and distribution contracts, ones with real power to drive performance. Why has there been no inventory for the Lifestyle condoms in markets where it was previously available (Australia, Canada, UK for example). Why are the sales for Betafem (Vivagel) in the UK apparently tailing off (if feedback is anything to go by). Who is monitoring the advertising performance of distributors?

The company needs marketing and advertising expertise and it needs it urgently.